The diversified medical and personal care products maker said Q4 EPS rose 5% to $1.19, beating expectations by 2 cents. Sales climbed 8% to $17.56 bil, slightly below views. U.S. sales rose 6.8% and int'l sales jumped 8.9%. Prescription drug sales increased 7% to $6.52 bil on high demand for Johnson & Johnson's (JNJ) arthritis, psoriasis and HIV medications. But sales at the consumer products division fell 3% to $14.4 bil on Tylenol recalls. Johnson & Johnson sees '13 EPS of $5.35-$5.45, below analyst targets of $5.49. Shares fell 0.7%.